What is HC Wainwright’s Forecast for CAPR FY2024 Earnings?

Capricor Therapeutics Inc (NASDAQ:CAPR) – Stock analysts at HC Wainwright raised their FY2024 earnings per share estimates for shares of Capricor Therapeutics in a research report issued on Thursday, November 14th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will earn ($1.33) per share for the year, up from their prior estimate of ($1.38). HC Wainwright currently has a “Buy” rating and a $77.00 target price on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Capricor Therapeutics’ Q4 2024 earnings at ($0.30) EPS, FY2025 earnings at ($1.14) EPS and FY2026 earnings at ($0.11) EPS.

A number of other equities analysts have also recently weighed in on CAPR. Oppenheimer reissued an “outperform” rating and issued a $15.00 price target on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Cantor Fitzgerald lifted their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. Maxim Group boosted their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. Finally, Piper Sandler began coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They issued an “overweight” rating and a $35.00 price objective for the company. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $34.50.

Capricor Therapeutics Stock Up 0.4 %

Shares of Capricor Therapeutics stock opened at $18.46 on Monday. Capricor Therapeutics has a 12-month low of $2.87 and a 12-month high of $23.40. The firm has a market capitalization of $839.38 million, a PE ratio of -17.42 and a beta of 4.00. The stock’s fifty day moving average is $15.78 and its 200-day moving average is $8.68.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CAPR. BNP Paribas Financial Markets purchased a new stake in shares of Capricor Therapeutics during the 1st quarter worth about $40,000. Vanguard Group Inc. raised its position in Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after acquiring an additional 200,499 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Capricor Therapeutics by 12.8% in the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after acquiring an additional 9,040 shares during the last quarter. Rhumbline Advisers bought a new stake in Capricor Therapeutics in the second quarter worth approximately $147,000. Finally, Main Street Financial Solutions LLC increased its stake in shares of Capricor Therapeutics by 37.5% during the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 7,500 shares during the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Insider Transactions at Capricor Therapeutics

In related news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the company’s stock in a transaction dated Friday, September 20th. The shares were acquired at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the completion of the purchase, the insider now owns 7,090,351 shares of the company’s stock, valued at $38,004,281.36. The trade was a 65.21 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 12.00% of the stock is owned by insiders.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.